23:42:17 Europe / Stockholm

Bifogade filer

Kurs & Likviditet

Kursutveckling och likviditet under dagen för detta pressmeddelande

Kalender

2024-05-29 Kvartalsrapport 2024-Q1
2024-05-15 Ordinarie utdelning GEAN 0.00 NOK
2024-05-14 Årsstämma 2024
2024-02-29 Bokslutskommuniké 2023
2023-11-20 Extra Bolagsstämma 2023
2023-11-16 Kvartalsrapport 2023-Q3
2023-08-30 Kvartalsrapport 2023-Q2
2023-05-25 Kvartalsrapport 2023-Q1
2023-05-12 Ordinarie utdelning GEAN 0.00 NOK
2023-05-11 Årsstämma 2023
2023-02-17 Bokslutskommuniké 2022
2022-11-01 Kvartalsrapport 2022-Q3
2022-08-18 Kvartalsrapport 2022-Q2
2022-05-13 Kvartalsrapport 2022-Q1
2022-04-29 Ordinarie utdelning GEAN 0.00 NOK
2022-04-28 Årsstämma 2022
2022-02-18 Bokslutskommuniké 2021
2021-11-09 Kvartalsrapport 2021-Q3
2021-09-20 Extra Bolagsstämma 2021

Beskrivning

LandNorge
Lista5542285
SektorHälsovård
IndustriBioteknik
Genetic Analysis är verksamma inom medicinteknik. Bolaget bedriver forskning och utveckling inom området för diagnostik, med störst fokus mot mänsklig mikrobiomet. Tekniken utgår ifrån bolagets forskningsplattform och IVD-produkterna används exempelvis för testtagning och analys av bakterier och virus. Störst verksamhet återfinns inom den nordiska marknaden och produkterna vidaresäljs huvudsakligen till laboratorier. Bolaget har sitt huvudkontor i Oslo, Norge.
2023-06-08 08:00:00

OSLO, NORWAY - 8 June 2023: Molecular diagnostics specialist, Genetic Analysis AS ("GA") has entered a distribution agreement with ELTA90 Group ("ELTA90"), a Sofia based fast growing distributor of Laboratory diagnostics into the Balkan region with operations in several countries. One of ELTA90 focus areas is specialized molecular diagnostics for the clinical diagnostics and research market.  

Ronny Hermansen, CEO, Genetic Analysis, comments:
"GA is proud to have ELTA90 Group as a partner in the Balkan region and is thrilled to see that our GA-map® platform gets acknowledgement from customers in new markets globally. The GA-map® platform offers a high throughput lab testing platform with an integrated cloud-based software algorithm for immediate result presentation of the microbiome analysis.  As the regulatory requirements in Europe gets stricter, we are happy to see that more and more labs are appreciating our CE-IVD GA-map® solution."

The market demand for gut microbiome assessments is rapidly increasing globally in the private healthcare services, medical clinics, and academic research with focus on identifying and categorizing the patient's microbiota. Together with ELTA90, GA can now offer its standardized gut microbiome testing platform to the Balkan countries to meet the growing interest and raise awareness of the impact of microbiota alteration and dysbiosis.

Dr. Theodor Zamfirov, CEO, ELTA90, comments:
"E90 are excited to offer the GA-map® Microbiome testing platform to our Lab customers all over the Balkan region, as we see that the demand for accurate, fast turnaround microbiome testing is increasing rapidly. GA-map® will be a great complementary to our growing business of specialty molecular diagnostics, as several labs in the Balkan countries are focusing on supplying the European market with high quality diagnostics. The core value of ELTA90 is to offer the highest quality products to our customers, and we are proud to add GA-map® to our portfolio of high-end products."